Nangibotide

N/A

Report date: 2023/01/05 20:00:47
NME

Base Information

Drug NameNangibotide
Drug Alias NameTLT1-LR12CardioTREMTREM-like-transcript-1-derived-peptideMotremLR-12
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTriggering receptor expressed on myeloid cells 1 inhibitors
TargetsTriggering receptor expressed on myeloid cells 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Shock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsDenmark +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInotrem
China Registration ClassN/A

Develop Information

Active CompaniesInotrem
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Shock, Septic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A